γδ T Cell Immunotherapy-A Review

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Vγ9Vδ2 T cell immunotherapy has emerged as a significant area of cancer treatment research over the last decade.
• Numerous clinical trials have investigated its efficacy against both solid tumors and hematological malignancies.

Purpose of the Study:

• To review existing clinical studies and reports on Vγ9Vδ2 T cell-based cancer immunotherapy.
• To discuss current challenges and potential improvements in Vγ9Vδ2 T cell activation and expansion methods.

Main Methods:

• Review of clinical trials and scientific literature concerning Vγ9Vδ2 T cell immunotherapy.
• Analysis of in vivo and ex vivo expansion strategies for Vγ9Vδ2 T cells.

Main Results:

• In vivo expansion using phosphoantigens or nitrogen-containing bisphosphonates (N-bis) has demonstrated safety in early clinical trials.
• Persistent issues include activation-induced T cell anergy and a reduction in peripheral Vγ9Vδ2 T cell counts post-stimulation.
• Ex vivo expansion of Vγ9Vδ2 T cells is challenging in advanced cancer patients with low initial cell numbers.

Conclusions:

• While Vγ9Vδ2 T cell immunotherapy holds therapeutic potential, overcoming challenges in cell activation, expansion, and patient-specific limitations is crucial.
• Further development is needed to enhance the effectiveness and applicability of Vγ9Vδ2 T cell-based cancer treatments.